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Background. Enhanced gene expression for the renin-
angiotensin system (RAS) is detected in glomerular mesangial
cells in IgA nephropathy (IgAN). Preliminary studies showed a
reduced glomerular gene expression of angiotensin II subtype
1 receptor (AT1R), suggesting a regulatory response to high
intrarenal angiotensin II (Ang II) concentration in IgAN.
Methods. We examined the effect of polymeric IgA1 (pIgA1)
from patients with IgAN on the expression of Ang II receptors
in cultured human mesangial cells (HMC).
Results. Polymeric IgA1 from patients with IgAN down-
regulated the expression of AT1R in HMC in a dose-dependent
manner. When similar experiments were conducted with addi-
tion of an angiotensin-converting enzyme inhibitor (captopril)
or an AT1R antagonist (losartan), there was a significant in-
crease in the expression of AT1R. Blockade of Ang II with cap-
topril or losartan alone resulted in a stepwise increase of AT1R
in cultured HMC. Down-regulation of Ang II subtype 2 recep-
tor (AT2R) was not observed in HMC cultured with pIgA1 from
patients with IgAN. The acute suppressive effect of pIgA1 from
IgAN on the expression of AT1R was confirmed in HMC in-
cubated with IgA isolated from 15 IgAN patients, 15 healthy
subjects, and other glomerulonephritides control subjects. Re-
duced glomerular expression of AT1R (but not AT2R) was also
demonstrated in renal biopsies from patients with IgAN.
Conclusion. Our findings demonstrate an altered AT1R ex-
pression in HMC in response to raised intrarenal Ang II in
IgAN. Our in vitro studies also support that an imbalance of
AT1R and AT2R activity in HMC following exposure to pIgA
plays a significant pathogenetic role in the inflammatory injury
in IgAN.
The renin-angiotensin system (RAS) has been recog-
nized as a key factor in the progression of chronic renal
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failure. Angiotensin II (Ang II) plays a central role as a
mediator of glomerular hemodynamic adaptation and in-
jury. It has been suggested that Ang II-induced mesangial
cell contraction with efferent arteriolar vasoconstriction
initiates intraglomerular hypertension, and may eventu-
ally lead to enhanced matrix formation and renal fibro-
sis following increased synthesis of transforming growth
factor-b (TGF-b) [1]. Pharmacologic blockade of this sys-
tem, by either angiotensin-converting enzyme inhibitor
(ACEI) or angiotensin II subtype-1 receptor (AT1R) an-
tagonist, retards progression of glomerulosclerosis [2].
However, renal expression and regulation of the com-
ponents of the RAS have not been well studied in human
subjects. Changes in the plasma RAS do not reflect local
expression of the RAS in kidney [3, 4]. Study of intrarenal
expression and regulation of the RAS is necessary for
evaluating the role of the renin system on the kidney, and
hence, the therapeutic target in chronic renal diseases.
IgA nephropathy (IgAN), now recognized to be the
most common glomerulonephritis worldwide, runs an in-
dolent but slowly progressive course leading to end-stage
renal failure (ESRF) in 30% to 40% of patients over
30 years [5]. The hallmark of the disease is character-
ized by mesangial deposition of polymeric IgA1 (pIgA1),
proliferation of mesangial cells, increased synthesis of
extracellular matrix, and infiltration by macrophages,
monocytes, and T cells [6]. Recent data suggest serum
IgA from patients with IgAN are different from those of
healthy subjects and can exert pathophysiologic effect on
target cells [7, 8].
Genes encoding for renin, angiotensinogen, and
angiotensin-converting enzyme (ACE) are detected in
cultured mesangial cells and in mesangial cells in kid-
ney tissues from patients with IgAN [9]. However, the
information of the RAS in IgAN remains scarce and is
mainly limited to ACE-related polymorphism. So far,
the results on the pathogenetic role of different ACE
genotypes in IgAN remain divergent and inconclusive
[10]. Both AT1R and Ang II subtype 2 receptor (AT2R)
are expressed in the normal human kidney, as well as in
1403
1404 Lai et al: pIgA and angiotensin II receptors in IgAN
patients with glomerular disease [11]. The histologic dis-
tribution of these receptors supports the notion that both
receptors may have a physiologic role in normal and dis-
eased kidneys in humans. In the present study, we studied
the Ang II receptor expression in kidney of IgAN pa-
tients. Polymeric IgA1 isolated from patients with IgAN
was examined to determine any regulatory effect on the
expression of these receptors in human mesangial cells
(HMC).
METHODS
Experimental design
The study was conducted in accordance with the Decla-
ration of Helsinki, and was approved by the institutional
ethics committee for studies in human. All subjects (pa-
tients and healthy control patients) gave their written in-
formed consent for serum and tissue collections.
We first examined the glomerular expression of AT1R
and AT2R in patients with IgAN. Renal tissues were ob-
tained from nine normotensive patients with mild IgAN
(grade 1) admitted consecutively for diagnostic renal
biopsy with the presentation of microscopic hematuria.
The severity of renal pathology was classified into grade 1,
2, or 3, as previously described [12], and grade 1 pathology
indicated mesangial proliferation with no crescent, scle-
rosis, or tubulointerstitial changes. These nine patients
had normal creatinine clearance (>80 mL/min/1.73m2)
with proteinuria ranging from 0.5 to 1.3 g/day. They
had not previously received ACEI or AT1R antagonists.
Next, we studied the dose- and time-response profile of
the acute effect of pIgA1 from patients with IgAN on
the expression of Ang II receptors in cultured HMC.
Polymeric IgA1 were isolated from sera of five of these
patients selected randomly. The same IgA preparations
were used in the subsequent study of the Ang II pro-
duction and expression of AT1R in HMC following pro-
longed exposure to pIgA1.
For comparison of the immediate regulatory effect of
pIgA1 isolated from different groups of subject on the
expression of Ang II receptors in cultured HMC, pIgA1
was prepared from sera of another 15 patients with IgAN
randomly recruited from the clinic. Their histologic diag-
nosis was made at least 18 months prior to the study, and
their serum creatinine remained stable over the previous
12 months. Their proteinuria ranged from 0.1 to 2.9 g/day.
Their mean endogenous creatinine clearance was 74.6 ±
23.0 mL/min./1.73 m2. These patients varied in the histo-
logic severity with grade 1 in 5, grade 2 in 8, and grade
3 in 2. Control subjects included healthy volunteers and
patients with other glomerulonephritides. None of these
15 patients with IgAN or patients with other glomeru-
lonephritides received ACEI or AT1R antagonists for
blood pressure control during the study period.
Materials
RPMI 1640 and fetal bovine serum (FBS) were ob-
tained from Life Technologies (Rockville, MD, USA).
Jacalin agarose was obtained from Pierce (Rockford, IL,
USA). Rabbit polyclonal antibodies against antihuman
AT1 or AT2 receptor were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Superose FPLC column
was obtained from Amersham Pharmacia Biotech (Upp-
sala, Sweden). Consumables for electrophoresis were ob-
tained from Bio-Rad Laboratories (Hercules, CA, USA).
All other chemicals were obtained from Sigma (St. Louis,
MO, USA).
Morphologic and immunohistologic studies
All patients who underwent renal biopsy or control
subjects for blood collection were administered a sodium-
controlled diet (50 mmol/L per day) the week before
biopsy or blood collection. Diet compliance was checked
by evaluating the urinary excretion of sodium the day
before biopsy or blood collection.
As previously mentioned, renal tissues were obtained
from nine normotensive patients with mild IgAN (grade
1) consecutively admitted for diagnostic renal biopsy with
the presentation of microscopic hematuria. Control renal
tissues were obtained from the intact pole of kidneys re-
moved for single circumscribed tumor in five normoten-
sive subjects (comparable in age, sex, and race). Renal
biopsy specimens were processed for light, immunoflu-
orescent, and electron microscopy by standard meth-
ods [13]. The glomerular expression of AT1R or AT2R
was detected by immunohistochemical staining using
specific polyclonal antibodies for individual Ang II re-
ceptor. Briefly, dewaxed 5-lm paraffin sections were in-
cubated with 0.5% hydrogen peroxide for removal of
endogenous peroxidase activity. Nonspecific binding was
blocked by incubation of the slides for 30 minutes with
blocking buffer [5% normal goat serum and 3% bovine
serum albumin in phosphate-buffered saline (PBS)]. The
sections were then incubated with anti-AT1R or anti-
AT2R antibody (5 lg/mL) overnight. The bound anti-
bodies were visualized as brown color using the Dako
Envision Plus System. To ensure the specificity of the
staining, we performed the following labeling controls:
(1) the primary antibodies were substituted with preim-
mune rabbit immunoglobulins; (2) staining was car-
ried out without either the primary antibodies or the
peroxidase-labeled polymer; and (3) the primary anti-
bodies were preincubated with 5 mg/mL carboxyl ter-
minal peptides of AT1R or AT2R. Some sections were
counterstained with hematoxylin before mounting. The
intensity of the slide preparations was semiquantitatively
scored at 0, 1+, 2+, 3+, and 4+ by two of the authors in-
dependently without the knowledge of the nature of an-
tibodies using a grading as previously described [13]. Ten
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consecutive glomerular cross sections (gcs) were counted
at high-power field (× 400), and staining was graded on
a scale of (0) for no staining, (1+) for <5% of labeled
cells per gcs stained, (2+) for 5% to 10% of labeled cells
per gcs stained, (3+) for 10% to 15% of labeled cells per
gcs stained, and (4+) for >15% of labeled cells per gcs
stained.
Purification and characterization of polymeric and
monomeric IgA1 by jacalin affinity chromatography
and fast protein liquid chromatography (FPLC)
Following the histologic examination for Ang II recep-
tors, we then proceeded to determine whether IgA from
patients with IgAN exerted any regulatory effect on the
expression of these receptors in HMCs in vitro. IgA was
isolated from sera obtained from five of these patients se-
lected randomly for in vitro time and dose response stud-
ies. IgA1 was fractionated at room temperature by the
fast protein liquid chromatography (FPLC) system (Phar-
macia) as described previously [14]. Briefly, monomeric
IgA1 (mIgA1) and pIgA1 were separated by FPLC fol-
lowing jacalin affinity chromatography. The identity of
IgA after FPLC was confirmed by immunoblotting and
sodium dodecyl sulfate (SDS)-polyacrylamide gel elec-
trophoresis (PAGE). Every IgA preparation from each
individual patient was separated into mIgA1 or pIgA1 ac-
cording to molecular weight. Chromatography fractions
with MW 300 to 1000 kD were high-molecular-mass IgA
or pIgA1, whereas fractions with MW 50 to 300 kD were
low-molecular-mass IgA or mIgA1. Distinct mIgA1 and
pIgA1 fractions were separately prepared from each in-
dividual patient for subsequent incubation studies. The
content of IgG in the fraction was measured by an anti-
IgG enzyme-linked immunosorbent assay (ELISA). The
fractions were dialyzed and concentrated to 2 mL with
Centriprep (Amicon, Beverly, MA, USA) and stored at
−70◦C until use. The purity of IgA1 fractions was con-
firmed by SDS-PAGE and ELISA [14]
Culture of human mesangial cell culture
Isolation and characterization of HMCs were per-
formed as previously described [14]. Glomeruli were
prepared from the cortex of human cadaveric kidney
judged to be unsuitable for transplantation or from
the intact pole of kidneys removed for circumscribed
tumor. Histologic examination of these kidney sam-
ples revealed no renal pathology. Glomerular cells were
grown in RPMI 1640 medium supplemented with glu-
tamine (2 mmol/L), N-[2-hydroxyethyl]-piperazine-N’-
[2-ethanesulfonic acid] (HEPES) (10 mmol/L), penicillin
(50 U/mL), streptomycin (50 lg/mL), and FBS in an at-
mosphere of 5% CO2-95% air. Mesangial cells have a
stellate appearance and grow in clumps. They show a net-
work of intracellular fibrils of myosin, and they contract
in the presence of 1 nmol/L of Ang II. Mesangial cells
from a single nephrectomy sample at fourth to seventh
passage were used in our experiments.
Treatment of human mesangial cells with different IgA
preparations or RAS blockade
Human mesangial cells were grown to log phase
and harvested using 0.05% trypsin. The trypsinized-
recovered cells were subcultured onto 6-well culture
plates (1 × 106 per wells). The cells were arrested by
growing 24 hours in medium containing 0.5% FBS before
exposure to IgA preparations or RAS blockade at in-
creasing concentrations (0, 0.125, 0.25, 0.5, 1, or 2 mg/mL
for IgA, and 0, 1, 10, 100, 1000, and 10,000 nmol/L for cap-
topril or losartan) for 6 or 24 hours at 37◦C in replicates.
Preliminary experiments were conducted showing these
incubation periods were convenient and were associated
with optimal synthesis of mRNA (6 hours) and protein
(24 hours) for Ang II receptors. Cells were harvested for
RNA extraction and total cell extract preparation. The
AT1R or AT2R content of the mesangial cells was stud-
ied by Western blotting. Culture supernatants were also
collected for determination of Ang II.
Gene expression of AT1 and AT2 receptors in cultured
mesangial cells
Specific primers for AT1R, AT2R, and glyceraldehyde-
3-phosphate-dehydrogenase (GAPDH) were designed
from known GeneBank sequences (AT1R NM–004835;
AT2R U16957; GAPDH X01677). The sequences of
each primers were as follows: (1) AT1R, sense primer
5′-GAT GAT TGT CCC AAA GCT GG-3′ and anti-
sense primer 5′-TAG GTA ATT GCC AAA GGG CC-3′;
(2) AT2R, sense primer 5′-AAG AAG AAA TCC
CTG GCA AGC-3′ and antisense primer 5′-CTT GGT
CAC GGG TTA TCC TGT-3′; and (3) GAPDH, sense
primer 5′-ACCACAGTCCATGCCATCAC-3′ and an-
tisense primers 5′-TCCACCACCCTGTTGCTGTA-3′.
We performed reverse transcription and polymerase
chain reaction (PCR) as described [15] using the follow-
ing profile: first cycle, 94◦C for three minutes, 55◦C for one
minute, 72◦C for one minute; second to 30th cycles, 95◦C
for 45 seconds, 55◦C for 40 second, 72◦C for 45 seconds.
The final cycle was 94◦C for one minute and 72◦C for
10 minutes. The PCR products from AT1R or AT2R and
control (GAPDH) amplicons were mixed and separated
by 1.5% wt/vol agarose gels, stained with ethidium bro-
mide, and the gel image was captured and analyzed using
the Gel Doc 1000 Gel Documentation System and Quan-
tity One software (Bio-Rad Laboratories, Ltd.). We semi-
quantitated the result of Ang II receptor mRNA yield as
a ratio of AT1R or AT2R amplicon to GAPDH ampli-
con. We took all necessary steps cautiously to ensure the
validity of the results as previously described [16].
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Determination of Ang II receptor protein in cultured
human mesangial cells
Homogenized human mesangial cells treated with dif-
ferent IgA preparation or following RAS blockade were
harvested and dissolved in protein extraction buffer con-
taining protease inhibitor cocktails, and the protein con-
centrations were measured by a modified Lowry method
using bovine serum albumin as standard (DC protein
assay kit; Bio-Rad). The extracts were spun at 10,000g
for 5 minutes at 4◦C to remove cell debris, and 50 lg of
protein electrophoresed through a 15% SDS-PAGE gel
before transferring to a polyvinylidene fluoride (PVDF)
membrane. After blocking for 1 hour at room tempera-
ture in blocking buffer (1% gelatin in PBS with 0.05%
Tween 20), the membrane was incubated for 16 hours
with anti-AT1R (1:1000) or anti-AT2R in PBS-Tween.
The membrane was washed and incubated for 2 hours
at room temperature with a peroxidase-labeled goat
antirabbit immunoglobulin (Dako) and detected with
enhanced chemiluminescence (ECL) plus chemilumines-
cent detection reagent (Amersham Pharmacia Biotech,
Arlington, IL, USA). The Western blotting images were
scanned on a flatbed scanner and the density of the bands
was quantitated using ImageQuant software (Molecu-
lar Dynamic, Sunnyvale, CA, USA). Densitometry re-
sults were reported as average arbitrary integrated values
(units). The results of Ang II receptor proteins obtained
by immunoblotting were further validated using flow cy-
tometry as previously described [14].
Determination of Ang II in supernatant from cultured
human mesangial cells
Angiotensin II was measured by an enzyme immunoas-
say using an anti-Ang II Fab’ monoclonal antibody la-
beled with acetylcholinesterase [17] (SPI bio, Massy
Cedex, France). The minimum detectable concentration
was 1 pg/mL, and the intra-assay coefficient of variation
was 7%.
Comparison of the regulatory effect of pIgA1 from IgAN
patients and control subjects on the expression of Ang II
receptors in mesangial cells
The effect of pIgA1 from patients with IgAN on the
expression of Ang II receptors in mesangial cells was fur-
ther studied in another 15 Chinese patients with primary
IgAN, as previously mentioned. Twenty milliliters of
blood were collected from each patient at clinical quies-
cence (a period free of macroscopic hematuria or mucosal
infection and urinary erythrocyte count <10,000/mL in
uncentrifuged urine). The serum was isolated and frozen
at −20◦C until for isolation of IgA1 by a jacalin-agarose
affinity column. Serum IgA level was determined by
nephelometry.
Fifteen healthy subjects (8 males and 7 females),
matched in age and race with no microscopic hematuria
or proteinuria, were used as healthy control subjects. Pa-
tients with Henoch-Schonlein purpura (HSP) (N = 10),
lupus nephritis (N = 10), minimal change nephropathy
(MCN) (N = 10), and membranous nephropathy (MGN)
(N =10) were recruited as disease control subjects. Serum
was similarly collected from these individuals for purifi-
cation of IgA.
Detection of Ang II-induced early apoptosis in human
mesangial cells by Western blotting
Cell extracts were prepared from homogenized hu-
man mesangial cells treated with different IgA prepa-
rations, or following RAS blockade for 24 hour as
described above. Early apoptosis was detected by West-
ern blotting using monoclonal anti-poly[ADP-ribose]
polymerase (PARP) antibody (Cell Signaling Technol-
ogy) that recognized the 89 kD cleaved PARP frag-
ment. The membrane was washed and incubated for
2 hours at room temperature with a peroxidase-labeled
goat antimouse immunoglobulin (Dako) and the reaction
was detected with ECL plus chemiluminescent detection
reagent (Amersham).
Ang II production and expression of AT1R in HMC
following prolonged exposure to pIgA
In order to find out whether short and prolonged expo-
sure to pIgA exerts different regulatory effect on HMC,
HMC were subcultured onto 6-well culture plates (0.5 ×
106 per wells). The cells were exposed to pIgA prepara-
tion from four patients with IgAN (0.5 mg/mL) at dif-
ferent time intervals (from 12 hours to 16 days). Culture
medium was changed every four days with fresh pIgA
preparation (0.5 mg/mL) added. At each time point, cul-
ture supernatants were saved for assay of Ang II. Total
cell lysate was prepared for analysis of AT1R and AT2R
expression by immunobloting. In parallel experiments,
cells were harvested at each time point, and cell prolifer-
ation was determined by expression of proliferating cell
nuclear antigen (PCNA) using flow cytometry.
Cell proliferation assay
Mesangial cells were harvested and fixed with abso-
lute methanol for 10 minutes at −20◦C followed by per-
meabilization with 0.5% NP-40 for 5 minutes. The cells
were washed once with staining buffer (PBS contain-
ing 1% FBS, 10% normal human serum, and 0.01%
sodium azide). The cells were incubated with a fluo-
roscein isothiocyanate (FITC)-conjugated monoclonal
anti-PCNA antibody (PCNA; clone PC10; Dako) for
30 minutes at room temperature. The cells were then
washed twice with staining buffer and resuspended in
PBS containing 1% FBS for flow cytometry analysis.
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Fig. 1. Representative glomerular staining of
angiotensin II type 1 receptor (AT1R) and
angiotensin II type 2 receptor (AT2R) in nor-
mal kidney and in IgAN. Decreased glomeru-
lar expression of AT1R was observed in renal
biopsies from patients with IgAN. In con-
trast, no difference in glomerular expression
of AT2R was observed in glomeruli from con-
trols or from patients with IgAN (hematoxylin
and eosin, magnification ×200).
Isotype-matched antibody was used as a control, and at
least 5000 cells were counted. The results were expressed
as mean fluorescence channel (MFI).
Statistics
All data (from patients or cell culture experiments)
were expressed as mean± standard deviation (SD). Inter-
group differences for continuous variables were assessed
by the unpaired t test except in concentrations exceed-
ing the in vivo relevance (for pIgA1) or the therapeutic
level (for captopril or losartan). The mRNA expression or
protein synthesis of Ang II receptors in cultured cells
following exposure to different concentrations of IgA
preparations or RAS blockade were analyzed with mul-
tivariate analysis of variance (ANOVA) for repeated
measures. All P values quoted are two-tailed, and the
significance is defined as P < 0.05.
RESULTS
Glomerular expression of Ang II receptors
Glomerular immunoreactive AT1R or AT2R protein
was found within mesangial cells in normal glomeru-
lus (Fig. 1A and C). Both arteriolar endothelium and
glomerular epithelial cells contained immunoreactive
AT1R and AT2R protein. These receptors were also de-
tected in tubular epithelium (picture not shown). In kid-
ney biopsies from patients with IgAN, immunostaining
revealed a pattern of reduced AT1R protein but not in
AT2R protein (Fig. 1B and D).
The intensity of the slide preparations was visually
scored independently from 0 to 4+ by two pathologists
without the knowledge of the nature of antibodies. In
general, there was good concordance of the score, and
no sample had a discordance of score greater than one
grade. Glomerular immunostaining for AT1R was signif-
icantly lower in patients with IgAN (mean score 1.0 vs.
1.8 in control subjects, P = 0.012) (Fig. 2A). Similar find-
ings were not detected in glomerular immunostaining for
AT2R (mean score of 2.33 in IgAN vs. 3.0 in control sub-
jects, P = 0.255) (Fig. 2B).
Expression of Ang II receptors in cultured human
mesangial cells
Inhibition of the ACE following incubating the HMC
with captopril led to an increased gene expression
of AT1R in a dose-dependent manner that peaked
at a concentration of 1000 nmol/L (Fig. 3A). Simi-
larly, blockade of the AT1R by specific antagonist also
resulted in a stepwise increase in gene expression of
AT1R in HMC, and the effect peaked at a concentration
of 1000 nmol/L. The findings of AT1R protein expression
in cultured mesangial cells incubated with either ACEI or
AT1R antagonist were parallel to those of mRNA signals
(Fig. 3B). More interestingly, pIgA1 from patients with
IgAN significantly down-regulated the gene and protein
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Fig. 2. (A) Glomerular expression of angiotensin II type 1 recep-
tor (AT1R) was reduced in renal biopsies from patients with IgAN
when compared with normal kidney. (B) Glomerular expression of an-
giotensin II type 2 receptor (AT2R) was not reduced in renal biopsies
from patients with IgAN when compared with normal kidney.
expression of AT1R in a dose-dependent manner reach-
ing a 8% and 17% protein decrease at concentrations of
0.25 and 0.5 mg/mL, respectively (Fig. 4). Despite mIgA1
from patients with IgAN also down-regulated the protein
expression of AT1R in a similar dose-dependent manner,
yet the magnitude was small. Similar experiments were
also performed with pIgA1 from five matched healthy
volunteers. Polymeric IgA1 from patients with IgAN
exerted more down-regulation of the gene and protein ex-
pression of AT1R in HMC than that from healthy volun-
teers, especially at concentration higher than 0.25 mg/mL
(Fig. 5).
In contrast, up-regulatory effect on AT2R protein ex-
pression was not observed in cultured HMC incubated
with either ACEI or AT1R antagonist (Fig. 6A). Sim-
ilarly, pIgA1 isolated from patients with IgAN exerted
no effect on the AT2R protein expression in cultured
mesangial cells (Fig. 6B). The findings of gene expres-
sion of AT2R in cultured mesangial cells incubated with
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Fig. 3. (A) Up-regulation of angiotensin II type 1 receptor (AT1R)
mRNA in cultured human mesangial cells incubated with captopril or
losartan [a group and “within” dose interaction, P < 0.0001 by mul-
tivariate analysis of variance (MANOVA)]. Measurement of AT1R
mRNA in human mesangial cells (HMC) incubated with captopril at
different concentrations differed significantly with each other (P <
0.05) except for measurements between 0 and 1 nmol/L, between 1
and 10 nmol/L, and between 10 and 100 nmol/L. Measurement of AT1R
mRNA in HMC incubated with losartan at different concentrations dif-
fered significantly with each other (P < 0.05) except for measurements
between 0 and 1 nmol/L, and between 1 and 10 nmol/L. The results rep-
resent the mean ± SD of five separate experiments. (B) Increased AT1R
protein synthesis in cultured HMC incubated with captopril or losar-
tan (a group and “within” dose interaction, P < 0.0001 by MANOVA).
Measurement of AT1R protein in HMC incubated with captopril at
different concentrations differed significantly with each other (P <
0.05) except for measurements between 0 and 1 nmol/L, between 0 and
10 nmol/L, and between 1 and 10 nmol/L. Measurement of AT1R pro-
tein in HMC incubated with losartan at different concentrations differed
significantly with each other (P < 0.05). The results represent the mean
± SD of five separate experiments.
captopril, losartan, or IgA preparations were parallel to
those of protein synthesis (data not shown).
The results of Ang II receptor proteins obtained by im-
munoblotting were validated by flow cytometry. The cor-
relation coefficients between immunoblotting and flow
cytometry measurements for AT1R and AT2R were 0.907
and 0.926, respectively.
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Fig. 4. (A) Down-regulation of angiotensin II type 1 receptor (AT1R)
mRNA in cultured human mesangial cells incubated with pIgA1 prepa-
rations from IgAN patients [a group and “within” dose interaction,
P < 0.0001 by multivariate analysis of variance (MANOVA)]. Mea-
surement of AT1R mRNA in HMC incubated with pIgA at different
concentrations differed significantly with each other (P < 0.05) ex-
cept for measurements between 0 and 0.125 mg/mL, and between 0.5
and 1 mg/mL. No down-regulation of AT1R mRNA in cultured hu-
man mesangial cells incubated with mIgA1 preparations from IgAN
patients was observed. The results represent the mean ± SD of five
separate experiments. (B) Decreased AT1R protein synthesis in cul-
tured human mesangial cells incubated with pIgA1 preparations from
IgAN patients (a group and “within” dose interaction, P < 0.0001 by
MANOVA). Measurement of AT1R protein in HMC incubated with
pIgA1 at different concentrations differed significantly with each other
(P < 0.05). Incubation of human mesangial cells with mIgA preparation
from IgAN patients resulted in a reduction in AT1R protein synthesis,
but of a small magnitude. The results represent the mean ± SD of five
separate experiments.
Effect of blocking the RAS in cultured HMC
preincubated with IgA
Next, we preincubated HMC with optimal dose of
IgA for 4 hours to down-regulate the AT1R expres-
sion. Polymeric IgA1 (0.5 mg/mL) suppressed the AT1R
expression more than mIgA1 at equivalent concentra-
tion or control medium (Fig. 7). The mesangial expres-
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Fig. 5. Expression of angiotensin II type 1 receptor (AT1R) in human
mesangial cells (HMC) incubated with pIgA1 from patients with IgAN
(N = 5) or from matched healthy volunteers (N = 5). Polymeric IgA1
from patients with IgAN exerted more down-regulation of the gene
and protein expression of AT1R in HMC than that from healthy volun-
teers, especially at concentration higher than 0.25 mg/mL. The results
represent the mean ± SD.
sion of AT1R increased when HMC preincubated with
pIgA1 was further treated with captopril (100 nmol/L)
or losartan (100 nmol/L). Identical experiments done
with mIgA1 demonstrated a similar pattern for AT1R ex-
pression, but the magnitude of the down-regulation was
smaller than pIgA1. AT2R expression in HMC was not
altered by preincubation with pIgA1 or mIgA (Fig. 8A).
Subsequent treatment with captopril or losartan exerted
no change in AT2R expression.
Comparison of the regulatory effect of pIgA1 from IgAN
patients and control subjects on the expression of Ang II
receptors in mesangial cells
The suppressive effect of pIgA1 in patients with IgAN
on the AT1R expression in mesangial cells was com-
pared between 15 IgAN patients with 15 healthy con-
trol subjects comparable in age and sex. The serum IgA
level in patients with IgAN (2.96 ± 1.13 g/L) was signifi-
cantly higher than that of healthy control subjects (1.81 ±
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sion in cultured HMC. (B) pIgA1 or mIgA1 isolated from patients with
IgAN exerted no effect on the AT2R protein expression in cultured
mesangial cells. The results represent the mean ± SD of five separate
experiments.
0.82 g/L, P < 0.001). No IgM was detected in the IgA
fractions. IgG represented 0.1% of total protein in IgA
fractions as measured by ELISA. Studies of IgA in FPLC
fractions by IgA ELISA showed that mIgA1 amounted
to 90% of total IgA1 from either control subjects or pa-
tients (data not shown). Despite the IgA was isolated
during clinical quiescence, pIgA1 from patients induced
a significantly less AT1R than cells incubated with pIgA1
from healthy control subjects (P < 0.025 and < 0.005 for
mRNA and protein, respectively) (Fig. 9).
Human mesangial cells were also incubated with pIgA1
from different disease groups to explore whether IgA
preparations from other glomerulonephritides also sup-
pressed the AT1R expression in HMC. Polymeric IgA1
prepared from patients with other glomerulonephritides
did not exert similar suppressive effect as observed in
pIgA1 isolated from patients with IgAN (Fig. 9). In
contrast, the effect of pIgA1 isolated from different
glomerulonephritides (including IgAN) on the mesangial
expression of AT2R did not differ from that of healthy
control subjects (Fig. 8B).
A good negative correlation was demonstrated be-
tween the Ang II levels in the cell supernatant and the
expression of AT1R of human mesangial cells incubated
with pIgA1 from patients with IgAN (r =−0.61, P < 0.02)
(Fig. 10). Similar correlation did not exist between the
supernatant level of Ang II and the expression of AT2R
of HMC following incubation with pIgA1 from patients
with IgAN.
Ang II-induced early apoptosis in human mesangial cells
incubated with IgA
As Ang II-induced apoptosis in renal proximal tubu-
lar cells and cardiomyocytes is mainly mediated through
activation of AT2 receptors [18, 19, 20], we tested for
early apoptosis in HMC incubated with pIgA from pa-
tients with IgAN using a monoclonal anti-PARP antibody
(Fig. 11A). The supernatant concentration of Ang II (4
to 6 pg/mL or 10−11 mol/L) in HMC released by incubat-
ing with pIgA was too low to induce apoptosis via the
binding to AT2R. Similarly, the supernatant concentra-
tion of Ang II in HMC following incubation with AT1R
antagonist failed to induce apoptosis. In contrast to hu-
man renal proximal tubular cells that became apoptotic
at an Ang II concentration of 10−9 mol/L [21], we showed
that apoptosis was inducible in HMC only at an Ang II
concentration ≥10−7 mol/L (Fig. 11B).
Ang II production and expression of AT1R in HMC
following prolonged exposure to pIgA
The supernatant concentration of Ang II peaked be-
tween day 1 and day 2 following initial culture with RMPI
1640 medium supplemented with pIgA preparation from
patients with IgAN (Fig. 12). Following the change of
fresh culture medium (with added pIgA) every four days,
the cultured HMC continued to synthesize Ang II, and
maintained a steady concentration toward the end of pro-
longed culture (day 16).
Following initial culture with RMPI 1640 medium sup-
plemented with pIgA preparation from patients with
IgAN, there was a stepwise reduction of AT1R expression
in cultured HMC in response to raised Ang II concen-
tration in the supernatant (Fig. 13). The maximum sup-
pression occurred on day 4 before the change of culture
medium. Subsequent to the initial suppression of AT1R
in the first 4 days, the down-regulation was gradually re-
versed despite the change of fresh culture medium (with
added pIgA) every four days. At day 16, the expression
of AT1R increased to values comparable to that on day 2.
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Fig. 7. (A) Gene expression of angiotensin II type 1 receptor (AT1R)
following blocking the renin-angiotensin system (RAS) in cultured hu-
man mesangial cells (HMC) preincubated with IgA1 preparations. In-
cubation with losartan (100 nmol/L) up-regulated the gene expression
of AT1R in resting HMC. ∗Signifies P < 0.002 as compared with HMC
incubated with losartan. Incubation with losartan (100 nmol/L) partly
reversed the down-regulatory effect of pIgA1 (0.5 mg/mL) on the gene
expression of AT1R in HMC. Similar effect was not seen with captopril
(100 nmol/L). # and ## signify P < 0.0025 and P < 0.02, respectively, as
compared with pIgA1-treated HMC that were subsequently incubated
with losartan. Incubation with losartan (100 nmol/L) partly reversed the
down-regulatory effect of mIgA1 (0.5 mg/mL) on the gene expression
of AT1R in HMC. †Signifies P < 0.03 as compared with mIgA1-treated
HMC that were subsequently incubated with losartan. The results rep-
resent the mean ± SD of five separate experiments. (B) AT1R syn-
thesis following blocking the RAS in cultured human mesangial cells
(HMC) preincubated with IgA1 preparations. Incubation with capto-
pril (100 nmol/L) or losartan (100 nmol/L) up-regulated the protein
synthesis of AT1R in resting HMC. ∗Signifies P < 0.01 as compared
with growth-arrested HMC and ∗∗signifies P < 0.05 compared with
HMC incubated with captopril. Incubation with captopril (100 nmol/L)
or losartan (100 nmol/L) partly reversed the down-regulatory effect of
No alteration was observed with AT2R during prolonged
culture.
There was progressive increase in cell proliferation of
the cultured mesangial cells (MC) following initial cul-
ture with RMPI 1640 medium supplemented with pIgA
preparation from patients with IgAN (Fig. 14). Following
the change of fresh culture medium (with added pIgA)
every four days, the cultured HMC continued to prolif-
erate with maximal activity on day 8. Cell proliferation
was maintained toward the end of prolonged culture (day
16) at activity comparable to that on day 2. In contrast,
the proliferative activities of MC cultured with RMPI
1640 medium with or without supplement of IgG from
the same patient were lower than that with pIgA. Fur-
thermore, the proliferative activities were not maintained
with prolonged culture.
DISCUSSION
Increased Ang II activity is implicated in various renal
pathologic settings. There are two main Ang II receptors
(AT1R and AT2R) in human, and these receptors are
detected in the vasculature, in glomeruli, and in tubular
segments [11]. However, the molecular mechanism and
the Ang II receptor subtypes involved in different renal
diseases have not been fully identified. More recently,
the effects on renal tubules or glomerular mesangial cells
following the blockade of the RAS provide initial un-
derstanding of the role of these Ang II receptors in re-
nal pathophysiology. ACE inhibition or AT1R blockade
consistently produce natriuresis, whereas AT2R blockers
have no effect [22]. Luminal AT(1A) (basolateral type
1A) receptor mediates a biphasic regulation of bicarbon-
ate absorption in proximal tubules by luminal Ang II in
rodent, while no evidence is obtained for a role of AT2R
[23]. In contrast, Ang II induces apoptosis in proximal
tubules (human and rodent) via AT2R but not via AT1R
[18, 21]. Angiotensin II exerts a hypertrophic effect in
primary cultured mesangial cells [24], and induces cel-
lular proliferation upon interaction with platelet-derived
growth factor [25]. While RAS blockade by AT1R antag-
onist prevents proliferation of mesangial cell [25], AT2R
stimulation exerts a potent antiproliferative effect in cul-
tured rat mesangial cells [26]. The observation that AT2R
pIgA1 (0.5 mg/mL) on the protein synthesis of AT1R in HMC. #Sig-
nifies P < 0.01 as compared with HMC preincubated with pIgA alone,
and ## signify P < 0.01 compared with pIgA1-treated HMC that were
subsequently incubated with captopril (100 nmol/L). Incubation with
captopril (100 nmol/L) or losartan (100 nmol/L) partly reversed the
down-regulatory effect of mIgA1 (0.5 mg/mL) on the protein syn-
thesis of AT1R in HMC. †Signifies P < 0.001 compared with HMC
preincubated with mIgA alone, and †† signify P < 0.05 compared with
mIgA1-treated HMC that were subsequently incubated with captopril
(100 nmol/L). The results represent the mean ± SD of five separate
experiments.
1412 Lai et al: pIgA and angiotensin II receptors in IgAN
MGN MCN LN HSP lgAN Control
MGN
MCN
LN
HSP
lgAN
Control
B
40 60 80 100
AT2R protein, arbitrary units
140
120
100
80
60
40
20
0A
T2
R
 p
ro
te
in
, a
rb
itr
ar
y 
un
its
A
Gr
ow
th 
arr
es
ted
HM
C
Ca
pto
pri
l
10
0 n
mo
l/L
Lo
sa
rta
n
10
0 n
mo
l/L
pIg
A 0
.5 
mg
/m
L
pIg
A 0
.5 
mg
/m
L+
Ca
pto
pri
l 1
00
 nm
ol/L
pIg
A 0
.5 
mg
/m
L+
Lo
sa
rta
n 1
00
 nm
ol/L
m
IgA
 0.
5 m
g/m
L
m
IgA
 0.
5 m
g/m
L+
Ca
pto
pri
l 1
00
 nm
ol/L
m
IgA
 0.
5 m
g/m
L+
Lo
sa
rta
n 1
00
 nm
ol/L
Fig. 8. (A) Angiotensin II type 2 receptor (AT2R) synthesis in human
mesangial cells (HMC) was not altered by preincubation with pIgA1
or mIgA. Subsequent treatment with captopril or losartan exerted no
change in AT2R expression. The results represent the mean ± SD of
five separate experiments. Similar findings were detected in gene ex-
pression of AT2R (data not shown). (B) No difference in AT2R protein
synthesis is demonstrated in cultured human mesangial cells incubated
with pIgA1 (0.5 mg/mL) from patients with IgAN when compared with
pIgA1 from healthy or disease controls. The results represent the mean
± SD. Similar findings were detected in gene expression of AT2R (data
not shown). HSP, Henoch-Schonlein purpura; MCN, minimal change
nephropathy; MGN, membranous nephropathy.
expression is impaired in stroke-prone spontaneously hy-
pertensive rats (SHR) kidney in vivo and in mesangial
cells in vitro suggests the unbalanced expression of Ang II
receptors with exaggerated AT1R signaling during early
life in SHR may play a role in the programming for hy-
pertension and related renal injury [26].
The RAS has been implicated in the development of
progressive renal fibrosis in IgAN [27, 28]. Local Ang
II hyperactivity is indirectly demonstrated by functional
tests in IgAN patients [29]. Angiotensin II plays a piv-
otal role in the glomerulosclerosis through induction of
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Fig. 9. (A) Angiotensin II type 1 receptor (AT1R) gene expression
and (B) AT1R protein synthesis in cultured human mesangial cells in-
cubated with pIgA1 (0.5 mg/mL) from normal controls, IgAN, HSP,
lupus nephritis, MCN, and MGN. All IgAN patients and disease con-
trols were in clinical quiescence. Polymeric IgA1 from patients with
IgAN induced a greater suppression of AT1R mRNA or protein by
HMC than pIgA1 from healthy or disease controls. ∗ and ∗∗ signify
P < 0.025 and P < 0.005 in AT1R mRNA and AT1R protein, respec-
tively, compared with HMC incubated with pIgA1 from healthy or dis-
ease controls. HSP, Henoch-Schonlein purpura; MCN, minimal change
nephropathy; MGN, membranous nephropathy. The results represent
the mean ± SD.
TGF-b expression in mesangial cells [30]. Despite the
presence of gene encoding for renin, angio-tensinogen,
and ACE in mesangial cells in human kidney [9], lit-
tle information is available about the RAS regulation in
the human kidney, and particularly, in kidney diseases.
The information of mesangial expression of Ang II re-
ceptors in glomerular disease is even scarcer. Using 125I-
labeled Ang II autoradiographic technique, Hale et al
[31] first suggested a local down-regulation of Ang II re-
ceptors despite proliferation of glomerular mesangium in
IgAN. In isolated glomeruli from 14 patients with IgAN,
Wagner et al [32] reported a reduced gene expression
of the AT1R. Although not significantly, an interesting
trend toward higher AT1R mRNA levels was observed
in patients on ACE inhibitors in that study. Most recently,
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Fig. 11. (A) Western blot analysis of human mesangial cells incubated
with culture medium with or without addition of Angiotensin II (Ang
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probed with a monoclonal anti-PARP antibodies. Cleaved PARP frag-
ments (89 kD) were not detected in these blots. Human mesangial cells
incubated with H2O2 (100 lmol/L) presented a positive control. (B)
Western blot analysis of human mesangial cells incubated with culture
medium containing increasing concentration of Ang II. Cleaved PARP
fragments (89 kD) were only just detected in blots with Ang II concen-
tration of 10−7mol/L.
Del Prete et al [28] reported an overexpression of RAS
genes (renin, angiotensinogen, and ACE) in kidney
biopsy of IgAN. In isolated glomeruli, an inverse rela-
tionship between these RAS genes and mRNA encoding
for AT1R or AT2R was observed. However, a paradoxic
finding of lower glomerular Ang II receptor mRNA levels
in controls than IgAN was observed since normal control
subjects had lower intrarenal RAS activities.
In the present study, we examined the Ang II receptor
expression in glomerular mesangial cells in IgAN. The
understanding of the local expression of RAS and Ang
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Fig. 12. Supernatant concentration of Angiotensin II (Ang II) in hu-
man mesangial cells undergoing prolonged culture. The cells were ex-
posed to pIgA preparation from four patients with IgAN (0.5 mg/mL)
at different time interval (from 12 hours to 16 days). Culture medium
was changed every four days with fresh pIgA preparation (0.5 mg/mL)
added. The concentration of Ang II in fresh culture medium (with added
pIgA) before use for cell culture was 0 pg/mL.
12 hour
day(s) 0 1 2 4 8 12 16
AT1R
AT2R
120
100
80
60
40
Al
l r
ec
ep
to
rs
 p
ro
te
in
, a
rb
itr
ar
y 
un
its
AT2
AT1
0 1 2 4 8 12 16 day(s)
12 hour
Fig. 13. Angiotensin II type 1 receptor (AT1R) and angiotensin II type
2 receptor (AT2R) protein expression in human mesangial cells under-
going prolonged culture. The cells were exposed to pIgA preparation
from four patients with IgAN (0.5 mg/mL) at different time interval
(from 12 hours to 16 days). The results represent the mean ± SD of four
separate experiments. The upper panels depict representative Western
blot analysis for AT1R and AT2R protein.
II receptors in mesangial cells is important in IgAN, as
the nephritis is developed following mesangial deposi-
tion of IgA mainly of the pIgA subclass. Although tubu-
lointerstitial damage is a better prognostic predictor than
glomerular damage in IgAN, IgA deposits are rarely de-
tected in renal tubules [33]. These pathologic findings sug-
gest the tubulointerstitial damage in IgAN is not a direct
event between pIgA1 and renal tubules, but rather an in-
direct sequel possibly mediated through soluble factor(s)
released following interaction between IgA deposits and
glomerular mesangial cells. Recently, we have demon-
strated that pIgA1 from patients with IgAN is capable
of inducing macrophage migration inhibitory factor and
tumor necrosis factor-a production, and up-regulating
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Fig. 14. Proliferative activity (measured by expression of PCNA) in
human mesangial cells undergoing prolonged culture. The cells were
exposed to culture medium alone, culture medium with added pIgA
preparation from patients with IgAN (0.5 mg/mL), or culture medium
with added IgG preparation from patients with IgAN (0.5 mg/mL).
Culture medium was changed every four days. There was progressive
increase in cell proliferation of the cultured mesangial cells (MC) ex-
posed to pIgA preparation from patients with IgAN, but not for MC
exposed to culture medium alone or culture medium supplemented with
IgG from patients with IgAN.
renin, Ang II, and TGF-b synthesis in HMC [34, 35]. In
this study, we detected immunoreactive AT1R or AT2R
protein in mesangial cells in glomerulus from normal or
IgAN kidney. These receptors were also detected in tubu-
lar epithelium and arteriolar endothelium. Semiquantita-
tive analysis showed a reduction of AT1R protein in HMC
from IgAN, but not for the AT2R protein. Our finding
is compatible with those of Hale et al [31] and Wagner
et al [32], supporting a local down-regulation of AT1R
in IgAN resulting from the negative feedback due to en-
hanced intraglomerular RAS, and hence, Ang II activity
[36, 37]. Our finding contrasts that of Del Prete et al [28],
in which gene expression rather than protein translation
for Ang II receptors and whole glomerulus rather than
mesangial cells were studied. Furthermore, our studied
subjects had a lower sodium-controlled diet (40% less)
than those studied by Del Prete et al [28].
Although an extension of our histologic findings to an
animal model of IgAN or an Ang II receptor knockout
animal model could be potentially useful in validating
our postulation, existing experimental [38] or transgenic
[39] mouse models of IgAN are far from satisfaction be-
cause none of them truly demonstrates all the essential
clinical and immunopathologic features of human IgAN.
Information inferred from transgenic mice does not even
correlate with human data [40]. The structure of human
IgA1 has no parallel, and IgA clearance mechanisms, sys-
temic and mucosal compartmentalization, and handling
differ across the species [41]. Instead, we further evalu-
ated our histologic findings by in vitro experiments study-
ing the regulatory effect of IgA on the expression of these
receptors in cultured HMC. Polymeric IgA1 and mIgA1
were selectively isolated from serum of our patients with
mild disease to determine the time- and dose-related
effect of different IgA fractions on the RAS in HMC.
For subsequent inhibitory studies and comparisons be-
tween patients and controls, a concentration of 0.5 mg/mL
was used for all IgA preparation in cell culture. This is
comparable to the serum concentration of pIgA concen-
tration (i.e., 0.35 mg/mL) in IgAN patients with an av-
erage serum total IgA of 3 g/L, of which 11% to 13%
are IgA1 of polymeric nature. In resting HMC, incuba-
tion with either an ACEI (captopril) or an AT1R antago-
nist (losartan) resulted in increased expression of AT1R
in a dose-dependent manner. With decreased binding of
Ang II to its receptor on HMC following blockade of the
RAS, the increased expression of AT1R is likely to me-
diate via the negative feedback loop. More interestingly,
pIgA1 from patients with IgAN also significantly down-
regulated the gene and protein expression of AT1R in a
dose-dependent manner, reaching a 17% protein reduc-
tion at a concentration of 0.5 mg/mL. The AT1R expres-
sion was restored to that of resting cells when HMC prein-
cubated with pIgA from patients with IgAN were treated
with either captopril or losartan. AT2R expression was
not affected by incubation with pIgA1 at these concen-
trations. The supernatant concentration of Ang II (10−11
mol/L) in HMC released by incubating with pIgA was too
low to induce apoptosis via the binding to AT2R [21]. One
may argue that our finding in resting cells may differ when
similar experiments are conducted in proliferating cells
[42]. We accepted our present experimental condition as
the in vitro findings parallel those in the renal biopsy from
IgAN patients. Our initial in vitro studies were performed
using IgA isolated from randomly selected patients with
mild histologic grading during clinical quiescence. The
suppressive effect of pIgA1 from patients with IgAN on
the RAS in mesangial cells was confirmed in another
15 patients with various histologic grading. Polymeric
IgA1 from IgAN patients down-regulated the AT1R ex-
pression in HMC when compared with cells incubated
with pIgA1 from healthy or disease control subjects com-
prising different glomerulonephritides. Of note is the dif-
ferent finding between IgAN and HSP, despite the latter
having similar renal histopathology. This could be due
to the difference in the size of circulating IgA immune
complexes, the subclass of IgA (k− versus j−light chain)
deposited in the mesangium, and the regulation of B cells
by T lymphocytes between the two glomerulonephritides
(reviewed in [43]). The regulatory effect of pIgA1 from
patients with IgAN on the AT1R and Ang II synthesis in
HMC shown in this and our recent studies [34, 35], and
the recent finding of increased nitric oxide generation
under blockade of RAS only in IgAN patients but not in
healthy subjects [44] reflects the uniqueness and impor-
tance of the RAS, as well as the unique pathogenetic role
of pIgA1 in IgAN.
The most interesting issue is the pathophysiologic sig-
nificance of the down-regulation of mesangial AT1R in
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IgAN. Regulation of Ang II receptors in renal tissues is
complex. In general, AT1R stimulates cell proliferation
while AT2R regulates cell growth inhibition and apopto-
sis [45, 46]. Previous studies showed a down-regulation
of glomerular AT1R mRNA in chronic renal failure, in-
cluding diabetic nephropathy and IgAN [32, 47]. Ang II
infusion studies in animal showed a reduction of AT1R
mRNA level in mesangial cells following exposure to Ang
II [36, 37]. The down-regulation is presumed to mediate
through the negative feedback due to enhanced intra-
glomerular Ang II activity. This hypothesis is supported
by the dose-response findings between RAS blockade
and the expression of AT1R, and the negative correla-
tion between supernatant Ang II levels and AT1R ex-
pression in HMC incubated with pIgA in our in vitro
experiments. It has been speculated that a decrease in
AT1R mRNA levels mirrors an adaptive response to high
intrarenal Ang II levels in human glomerulonephritis and
diabetes mellitus [32]. The obvious question is why such
adaptive mechanism operates in glomerulonephritides
such as IgAN. In IgAN, we hypothesize that this could
arise from the differential expression of Ang II recep-
tors in mesangial cells following the release of Ang II by
polymeric IgA. In renal proximal tubular cells exposed
to Ang II, the growth-stimulatory effects through AT1R
may be counter-balanced by AT2R-mediated apoptosis
and growth inhibition [18, 48]. Despite the fact that pIgA
from patients with IgAN induces Ang II release from
HMC, our novel findings suggest that the Ang II level
(10−11 mol/L) is unlikely to be sufficient to stimulate the
apoptotic (or even the antiproliferative) effect via en-
hanced expression of AT2R. Our data reveal the Ang
II concentration required to induce apoptosis in HMC
(>10−7 mol/L) is 100-fold higher than that of human re-
nal proximal tubules (10−9 mol/L) [21]. Unbalanced Ang
II receptor expression with exaggerated AT1R has shown
to contribute to hypertension and related renal injury in
different experimental models [26, 49]. Hence, we postu-
late that the defective counterbalance of AT1R by AT2R
in HMC exposed to pIgA from IgAN patients leads to
an adaptive down-regulation of the AT1R. An immedi-
ate down-regulation of mesangial AT1R expression will
ameliorate the proliferative and inflammatory changes
induced by Ang II released by pIgA. However, we en-
visage this adaptive mechanism in HMC may gradually
be altered with chronic exposure to Ang II released by
pIgA in IgAN. Failure to suppress the AT1R expres-
sion continuously in the presence of defective AT2R
activation is likely to permit the development of prolifer-
ative and inflammatory processes in the glomerulus that
may finally lead to progression of renal deterioration in
IgAN. This hypothesis has lent support from our study of
HMC following prolonged exposure to pIgA from IgAN.
The adaptive down-regulation of AT1R gradually disap-
peared despite the maintenance of significant Ang II con-
centration in the supernatant. Furthermore, there was
progressive increase in cell proliferation following pro-
longed culture of HMC with exposure to pIgA, but not
with plain culture medium or IgG from the same disease
subject.
CONCLUSION
Our findings support an altered AT1R expression in
HMC in response to raised intrarenal Ang II concentra-
tion in IgAN. An imbalance of AT1R and AT2R activity
in HMC following exposure to pIgA may play a signifi-
cant pathogenetic role in the glomerular inflammation in
IgAN.
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